Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
Pacira BioSciences (PCRX) has initiated Phase 2 clinical trials for PCRX-201, a novel gene therapy for knee osteoarthritis treatment. The first patient has been dosed in the ASCEND study, which will evaluate the safety and efficacy of this locally administered therapy.
The study will involve 135 patients aged 45-80 with knee OA, testing two doses (1.4 x 10¹⁰ and 1.4 x 10¹¹ genome copies) against saline. PCRX-201 uses a proprietary high-capacity adenovirus vector platform to boost IL-1Ra production, targeting inflammation in the knee joint.
The two-part trial's primary endpoint focuses on safety through Week 52, with secondary endpoints measuring pain and physical function. Initial topline results are expected by late 2026. In Phase 1, a single injection demonstrated pain relief lasting at least two years across all OA severity levels.
Pacira BioSciences (PCRX) ha avviato la fase 2 degli studi clinici per PCRX-201, una nuova terapia genica per il trattamento dell'osteoartrite del ginocchio. Il primo paziente è stato trattato nello studio ASCEND, che valuterà la sicurezza e l'efficacia di questa terapia somministrata localmente.
Lo studio coinvolgerà 135 pazienti di età compresa tra 45 e 80 anni affetti da OA al ginocchio, testando due dosi (1,4 x 10¹⁰ e 1,4 x 10¹¹ copie genomiche) rispetto a una soluzione salina. PCRX-201 utilizza una piattaforma proprietaria di vettore adenovirale ad alta capacità per aumentare la produzione di IL-1Ra, mirando all'infiammazione nell'articolazione del ginocchio.
Il principale obiettivo del trial in due parti si concentra sulla sicurezza fino alla settimana 52, con obiettivi secondari che misurano il dolore e la funzione fisica. I risultati preliminari attesi sono previsti entro la fine del 2026. Nella fase 1, un'unica iniezione ha dimostrato un sollievo dal dolore duraturo per almeno due anni in tutti i livelli di gravità dell'OA.
Pacira BioSciences (PCRX) ha iniciado ensayos clínicos de fase 2 para PCRX-201, una nueva terapia génica para el tratamiento de la osteoartritis de rodilla. El primer paciente ha sido tratado en el estudio ASCEND, que evaluará la seguridad y eficacia de esta terapia administrada localmente.
El estudio involucrará a 135 pacientes de entre 45 y 80 años con OA de rodilla, probando dos dosis (1.4 x 10¹⁰ y 1.4 x 10¹¹ copias genómicas) frente a solución salina. PCRX-201 utiliza una plataforma de vector adenoviral de alta capacidad para aumentar la producción de IL-1Ra, enfocándose en la inflamación de la articulación de la rodilla.
El objetivo principal del ensayo de dos partes se centra en la seguridad hasta la semana 52, con objetivos secundarios que miden el dolor y la función física. Se esperan resultados preliminares para finales de 2026. En la fase 1, una sola inyección demostró un alivio del dolor que duró al menos dos años en todos los niveles de gravedad de la OA.
Pacira BioSciences (PCRX)는 무릎 골관절염 치료를 위한 새로운 유전자 치료제인 PCRX-201의 2상 임상 시험을 시작했습니다. 첫 번째 환자가 ASCEND 연구에서 치료를 받았으며, 이 연구는 국소적으로 투여되는 이 치료법의 안전성과 효능을 평가할 것입니다.
이 연구는 무릎 OA에 걸린 45세에서 80세 사이의 135명 환자를 포함하며, 두 가지 용량(1.4 x 10¹⁰ 및 1.4 x 10¹¹ 유전자 복제본)을 생리식염수와 비교하여 테스트합니다. PCRX-201은 IL-1Ra 생산을 증가시키기 위해 고용량 아데노바이러스 벡터 플랫폼을 사용하여 무릎 관절의 염증을 목표로 합니다.
이 두 부분으로 구성된 시험의 주요 목표는 52주까지의 안전성을 중심으로 하며, 이차 목표는 통증과 신체 기능을 측정합니다. 초기 topline 결과는 2026년 말에 예상됩니다. 1상에서 단일 주사는 모든 OA 중증도 수준에서 최소 2년 동안 지속되는 통증 완화를 보여주었습니다.
Pacira BioSciences (PCRX) a lancé des essais cliniques de phase 2 pour PCRX-201, une nouvelle thérapie génique pour le traitement de l'arthrose du genou. Le premier patient a été traité dans l'étude ASCEND, qui évaluera la sécurité et l'efficacité de cette thérapie administrée localement.
L'étude impliquera 135 patients âgés de 45 à 80 ans atteints d'arthrose du genou, testant deux doses (1,4 x 10¹⁰ et 1,4 x 10¹¹ copies génomiques) par rapport à une solution saline. PCRX-201 utilise une plateforme de vecteur adénoviral à haute capacité pour augmenter la production d'IL-1Ra, ciblant l'inflammation dans l'articulation du genou.
Le principal objectif de l'essai en deux parties se concentre sur la sécurité jusqu'à la semaine 52, avec des objectifs secondaires mesurant la douleur et la fonction physique. Les premiers résultats préliminaires sont attendus d'ici la fin de 2026. Lors de la phase 1, une seule injection a montré un soulagement de la douleur durant au moins deux ans, quel que soit le degré de gravité de l'arthrose.
Pacira BioSciences (PCRX) hat klinische Studien der Phase 2 für PCRX-201, eine neuartige Gentherapie zur Behandlung von Kniearthrose, eingeleitet. Der erste Patient wurde in der ASCEND-Studie behandelt, die die Sicherheit und Wirksamkeit dieser lokal verabreichten Therapie bewerten wird.
Die Studie wird 135 Patienten im Alter von 45 bis 80 Jahren mit Knie-OA umfassen und zwei Dosen (1,4 x 10¹⁰ und 1,4 x 10¹¹ Genomkopien) gegen Kochsalzlösung testen. PCRX-201 verwendet eine proprietäre Hochkapazitäts-Adenovirus-Vektorplattform, um die IL-1Ra-Produktion zu steigern, und zielt auf Entzündungen im Kniegelenk ab.
Der primäre Endpunkt der zweigeteilten Studie konzentriert sich bis zur Woche 52 auf die Sicherheit, während sekundäre Endpunkte Schmerzen und körperliche Funktion messen. Erste Topline-Ergebnisse werden bis Ende 2026 erwartet. In Phase 1 zeigte eine einzige Injektion eine Schmerzlinderung, die mindestens zwei Jahre lang bei allen Schweregraden der OA anhielt.
- Phase 1 demonstrated unprecedented 2-year pain relief duration
- Part B will use new suspension-based manufacturing process for commercial scale-up
- Therapy shows potential for longer-lasting relief compared to current 3-6 month treatments
- Topline results not expected until late 2026
- Complex study design requiring 5-year patient follow-up
Insights
Pacira's advancement of PCRX-201 to Phase 2 represents a significant pipeline milestone in the company's evolution beyond its flagship EXPAREL franchise. The initiation of the ASCEND study positions Pacira to potentially disrupt the massive osteoarthritis market with a first-in-class gene therapy approach.
The technology's key differentiators are compelling: a locally-administered gene therapy that stimulates IL-1Ra production with an inducible promoter that activates only when inflammation is present. This mechanism addresses a fundamental limitation of current OA therapies - the inability to provide durable relief beyond 3-6 months.
Particularly noteworthy is the CEO's reference to the Phase 1 results showing pain relief lasting at least two years across all OA severity levels. If replicated in larger studies, this durability would represent a paradigm shift in OA management, potentially positioning PCRX-201 as a market leader.
The two-part study design with 135 patients is appropriately sized for a Phase 2, with the company wisely incorporating manufacturing process validation (Part B using commercial-scale suspension-based batch manufacturing) - a forward-thinking approach that could accelerate the path to market.
While topline results aren't expected until late 2026, this program strengthens Pacira's diversification strategy beyond its anesthetic portfolio. The company is making a calculated bet on gene therapy for musculoskeletal conditions - a novel approach that could yield significant returns if successful in this undertreated condition affecting millions globally.
-- Novel, locally administered gene therapy designed to boost cellular production of
anti-inflammatory protein IL-1Ra in the knee --
-- Initial topline results from two-part, randomized, double-blind, active-controlled study
expected late 2026 --
BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the first patient has been dosed in the Phase 2 ASCEND study of PCRX-201 (enekinragene inzadenovec) for the treatment of osteoarthritis, or OA, of the knee. PCRX-201 features an innovative design based on the company’s proprietary high-capacity adenovirus, or HCAd, gene therapy vector platform. It is injected locally into the knee joint to boost cellular production of interleukin-1 receptor antagonist (IL-1Ra), and block interleukin-1 pathway activation to improve chronic inflammation, pain, and function. PCRX-201’s unique design also features an inducible promoter to mimic the body’s natural response to inflammation by “turning on” the expression of IL-1Ra when inflammation is present in the joint and turning off expression once inflammation is quelled.
“We are excited to advance PCRX-201 into Phase 2 clinical development as it marks an important milestone on our 5x30 path to growth and value creation, as well as our transition into an innovative biopharmaceutical organization,” said Frank D. Lee, chief executive officer of Pacira. “There is a significant need for innovation in the treatment of OA of the knee, as current therapies are based on decades-old mechanisms and only provide up to three to six months of relief. In our large Phase 1 study, a single intra-articular injection of PCRX-201 was well tolerated and demonstrated unprecedented pain relief and durability across all levels of OA severity for at least two years. PCRX-201 has the potential to address the underlying chronic inflammatory processes that contribute to OA joint degeneration over time, with local administration that is contained in the joint – delivering medicine where it matters.”
Study Design
The two-part, multicenter ASCEND study will involve approximately 135 patients, 45 to 80 years old with painful OA of the knee at a Kellgren-Lawrence (K-L) Grade of 2, 3 or 4. Subjects will be randomly assigned to a treatment dose group and stratified by K-L Grade, a semiquantitative method for evaluating the severity of OA on a scale of 0-4.
ASCEND will evaluate two doses of PCRX-201, Dose A is 1.4 x 1010 genome copies (GC) and Dose B is 1.4 x 1011 GC. Patients will be randomized 1:1:1 to Dose A, Dose B or saline. All cohorts will receive concurrent pretreatment with an intraarticular corticosteroid (methylprednisolone 40 mg), a technique common in gene therapy dosing to improve tolerability and gene transfer.
Part A of the study will randomize approximately 45 patients and Part B will randomize approximately 90 patients. The drug product used in Part B of the study will be manufactured using the company’s newly developed, suspension-based batch manufacturing process intended for commercial scale-up. Pacira expects to report topline results from Part A of the study before the end of 2026.
For both Parts A and B of the study, the primary endpoint is the number and percent of treatment-emergent adverse events, adverse events of special interest, and serious adverse events for PCRX-201 plus steroid pretreatment versus saline plus steroid pretreatment from Week 1 through Week 52. The study’s secondary and exploratory endpoints include efficacy assessments such as changes in pain and physical function from baseline at Weeks 38 and 52. Efficacy will be measured using the Numerical Rating Scale (NRS); the Western Ontario and McMaster Universities Index (WOMAC), and the Knee Injury and Osteoarthritis Outcome Score (KOOS). Biomarkers, including structural endpoints, as well as immunogenicity and biodistribution will also be evaluated and all subjects will be followed for 5 years.
About PCRX-201
Pacira’s novel product candidate PCRX-201 (enekinragene inzadenovec), features an innovative design based on the company’s proprietary high-capacity adenovirus vector platform. It is currently being studied in the fundamental, underlying chronic inflammatory processes that contribute to “wear and tear” over time in osteoarthritis of the knee, a condition that affects more than 14 million individuals in the U.S. today.
In November 2024, Pacira reported promising data from a large Phase 1 study in which PCRX-201 provided sustained improvements in knee pain, stiffness, and function through two years following local administration, with a well-tolerated safety profile. These data were presented at the American College of Rheumatology’s annual ACR Convergence meeting at the American College of Rheumatology meeting. PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency. RMAT and ATMP are regulatory programs designed to expedite the development and review processes for promising therapies targeting a significant unmet need with preliminary clinical evidence indicating that the therapy has the potential to offer a major advantage over existing treatments. PCRX-201 is the first gene therapy to achieve these clinical results and earn these regulatory designations in osteoarthritis of the knee – a testament to its promise and potential.
About the High-capacity Adenovirus Vector Platform
In February 2025, in support of the company’s ‘5x30’ growth strategy, Pacira acquired GQ Bio Therapeutics and its novel high-capacity adenovirus (HCAd) vector gene therapy vector platform. This platform solves many of the challenges in the field of gene therapy that have prevented its utilization in treating common diseases, such as osteoarthritis.
Key features include:
- The HCAd vector is much more efficient at delivering genes into cells compared to many other gene therapies that rely on adenovirus associated virus, or AAV, vectors. As a result, the desired effect can be achieved with much smaller doses.
- The vector used in the HCAd platform can carry up to 30,000 base pairs of DNA, which enables gene therapy with multiple or larger genes compared to AAV vectors.
- Genetic medicines based on the HCAd platform can be administered locally and have the potential for redosing at therapeutically appropriate intervals.
- Lower dose levels and efficient delivery of genes into cells means that thousands of doses can be produced in a single batch. As a result, therapies built on the HCAd platform are expected to have a commercially attractive and viable cost of goods profile.
Beyond PCRX-201 and other product candidates in preclinical development, the company has identified numerous well-validated cytokines that could also be the basis for locally administered genetic therapies using the HCAd platform.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Forward-Looking Statements
Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the settlement described herein, ‘5x30’, our growth and business strategy; our future outlook, our intellectual property and patent terms, our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flow and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the “SEC”). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the SEC.
Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com
FAQ
What are the key endpoints for PCRX's Phase 2 ASCEND study of PCRX-201?
How many patients will be enrolled in Pacira's PCRX-201 Phase 2 trial?
What were the Phase 1 results for PCRX-201 in knee osteoarthritis?
When will Pacira (PCRX) report topline results from the PCRX-201 Phase 2 study?
